Cost analysis of erlotinib versus chemotherapy for first-line treatment of non–small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study …

C Chouaid, H Le Caer, R Corre, J Crequit, C Locher… - Clinical Lung Cancer, 2013 - Elsevier
Background A large proportion of elderly patients (> 70 years) with newly diagnosed NSCLC
are shown to be frail by a comprehensive geriatric assessment. This population is more …
被引用次数：19 相关文章

Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non–Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase …

C Chouaid, H Le Caer, R Corre… - Clinical Lung …, 2013 - clinical-lung-cancer.com
Background A large proportion of elderly patients (> 70 years) with newly diagnosed NSCLC
are shown to be frail by a comprehensive geriatric assessment. This population is more …

Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non-Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase 2 …

C Chouaid, H Le Caer, R Corre, J Crequit… - Clinical Lung …, 2013 - search.ebscohost.com
BACKGROUND: A large proportion of elderly patients (> 70 years) with newly diagnosed
NSCLC are shown to be frail by a comprehensive geriatric assessment. This population is …
[PDF] academia.edu

[PDF][PDF] Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non–Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective …

C Chouaid, H Le Caer, R Corre, J Crequit… - Clinical Lung …, 2013 - academia.edu
This study assessed the cost-effectiveness (limited to direct medical costs, from the third-
party payer perspective) of erlotinib followed by chemotherapy after progression, compared …

Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non-Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase 2 …

C Chouaid, H Le Caer, R Corre, J Crequit… - Clinical Lung …, 2013 - hero.epa.gov
This study assessed the cost-effectiveness (limited to direct medical costs, from the third-
party payer perspective) of erlotinib followed by chemotherapy after progression, compared …
[PDF] g-f-p-c.org

[PDF][PDF] Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non–small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective …

C Chouaid, H Le Caer, R Corre, J Crequit, C Locher… - gfpc.org
This study assessed the cost-effectiveness (limited to direct medical costs, from the third-
party payer perspective) of erlotinib followed by chemotherapy after progression, compared …

Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study …

C Chouaid, H Le Caer, R Corre… - Clinical lung …, 2013 - pubmed.ncbi.nlm.nih.gov
Background A large proportion of elderly patients (> 70 years) with newly diagnosed NSCLC
are shown to be frail by a comprehensive geriatric assessment. This population is more …

Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study …

C Chouaid, H Le Caer, R Corre, J Crequit… - Clinical Lung …, 2012 - europepmc.org
Background A large proportion of elderly patients (> 70 years) with newly diagnosed NSCLC
are shown to be frail by a comprehensive geriatric assessment. This population is more …

Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non–Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase …

C Chouaid, H Le Caer, R Corre, J Crequit, C Locher… - Clinical Lung …, 2013 - infona.pl
A large proportion of elderly patients (> 70 years) with newly diagnosed NSCLC are shown
to be frail by a comprehensive geriatric assessment. This population is more vulnerable to …

Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non–Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase …

C Chouaid, H Le Caer, R Corre, J Crequit, C Locher… - Clinical Lung …, 2013 - infona.pl
A large proportion of elderly patients (> 70 years) with newly diagnosed NSCLC are shown
to be frail by a comprehensive geriatric assessment. This population is more vulnerable to …